10-K: Fulgent Genetics: 2025 Revenue Growth Amidst Rising Losses

Fulgent Genetics reported a 14% revenue increase to $322.7 million in 2025, alongside a 42% rise in net loss to $60.5 million, driven by strategic acquisitions and R&D investments.

Summary

• Revenue increased by 14% to $322.7 million in 2025 from $283.5 million in 2024.
• Net loss attributable to Fulgent increased by 42% to $60.5 million in 2025 from $42.7 million in 2024.
• Gross profit increased by 22% to $130.9 million in 2025, with gross margin improving from 38% in 2024 to 41% in 2025.
• Operating expenses increased by 23% to $221.97 million in 2025.
• Acquired 100% of ANP Technologies, Inc. in July 2025, securing full ownership of patents for therapeutic candidates FID-007 and FID-022.
• Entered into definitive agreements in December 2025 to acquire selected assets of Bako Diagnostics and StrataDx for a total combined purchase price of approximately $55.5 million in cash, with closing expected in the first half of 2026.
• Purchased $106.3 million worth of Investment Tax Credits (ITCs) for $99.5 million in cash in 2025, resulting in a $6.8 million tax benefit.
• One large laboratory customer contributed $70.8 million, or 22%, of total revenue in 2025 and 2024, with expected reduced revenues from this customer in 2026.
• FID-007 Phase 1/1b clinical trial completed enrollment of 50 patients, observing a manageable safety profile and preliminary anti-tumor activity.
• FID-007 Phase 2 clinical trial enrollment completed in the second quarter of 2024 (up to 46 patients), with interim findings anticipated in June 2026 and full data readout by the second half of 2027.
• FID-022 Phase 1/1b clinical trial completed the first dose level in December 2025, the second in January 2026, and commenced dosing of the third dose level in February 2026, with a goal to determine a maximum tolerated dose within the next year.
• Made significant advancement in pre-clinical development of Antibody Drug Conjugates (ADCs) using a novel patented linker and payload platform technology, observing better efficacy over different tumors compared to benchmarks.
• Subject to ongoing Civil Investigative Demands (CIDs) from the U.S. Department of Justice (DOJ) and an audit inquiry from the U.S. Health Resources and Services Administration (HRSA) related to COVID-19 testing reimbursements.
• Recorded an accrual of $14.5 million in connection with the settlement of a professional liability matter.
• Maintained effective internal control over financial reporting as of December 31, 2025.
• Chief Scientific Officer and Laboratory Director, Hanlin Gao, entered into a Rule 10b5-1 sales plan on November 25, 2025, to sell up to 100,000 shares of common stock by January 31, 2027.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and strategic acquisitions are positive, the significant increase in net loss and cash burn from operations, coupled with the anticipated decline from a major customer and ongoing legal/regulatory uncertainties, indicate considerable financial headwinds and execution risks.

Positives

• Revenue increased by 14% to $322.7 million in 2025, driven by growth in precision diagnostics, anatomic pathology, and BioPharma services.
• Gross profit increased by 22% to $130.9 million, with gross margin improving from 38% in 2024 to 41% in 2025, reflecting optimized cost structures and operational efficiency.
• Successfully acquired ANP Technologies, Inc. in July 2025, securing full ownership of patents for therapeutic candidates FID-007 and FID-022, enhancing control over development and commercialization.
• Entered into definitive agreements to acquire Bako Diagnostics and StrataDx for $55.5 million, expected to expand anatomic pathology services and customer base.
• FID-007 Phase 1/1b clinical trial demonstrated a manageable safety profile and preliminary evidence of anti-tumor activity in heavily pre-treated patients.
• Completed enrollment for FID-007 Phase 2 clinical trial, with interim findings expected in June 2026, potentially accelerating the path to a Phase 3 trial.
• Progressed FID-022 Phase 1/1b clinical trial, commencing dosing of the third dose level in February 2026.
• Achieved significant advancement in Antibody Drug Conjugates (ADCs) pre-clinical development, showing superior efficacy over benchmarks.
• Received CE certification under the IVDR for its germline NGS system (FulgentExome and Fulgent Pipeline Manager) in July 2025, facilitating market access in the European Union.
• Purchased $106.3 million worth of Investment Tax Credits (ITCs) for $99.5 million in cash, resulting in a $6.8 million tax benefit for the period.
• Maintained a strong cash, cash equivalents, restricted cash, and marketable securities position of approximately $705.5 million as of December 31, 2025.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Net loss attributable to Fulgent increased significantly by 42% from $42.7 million in 2024 to $60.5 million in 2025.
• Operating expenses increased by 23% to $221.97 million in 2025, contributing to the increased net loss.
• Cash used in operating activities increased substantially to $101.6 million in 2025, compared to $21.1 million provided in 2024, primarily due to the purchase of Investment Tax Credits and timing of payments.
• Anticipates reduced revenues from a single large laboratory customer in 2026 (particularly through the second quarter), as this customer begins performing certain tests internally; this customer represented 22% of total revenue in 2025.
• Recorded a $14.5 million accrual in connection with the settlement of a professional liability matter.
• Recognized a $9.9 million impairment loss on its preferred stock investment in Helio Genomics during 2025.
• The company has a history of losses and may not be able to regain or sustain profitability in future periods.
• General and administrative expenses increased by 32% to $116.7 million, primarily due to higher legal and professional fees and provision for credit losses.

Risks

• Actual or attempted security incidents or breaches, loss of data, or other disruptions could expose the company to material liability and materially and adversely affect its business, financial condition, and reputation.
• Results of operations may fluctuate significantly from period to period and can be difficult to predict.
• The company has a history of losses and may not be able to regain or sustain profitability.
• Inability to successfully integrate any acquired businesses and technologies (e.g., Bako Diagnostics, StrataDx, ANP) may adversely affect business and results of operations.
• The company may incur liabilities as a result of acquisitions, including those not reflected or contemplated in the financial statements of acquired businesses.
• Revenue is often concentrated among a single large customer or a small number of larger customers, and the loss of or a reduction in sales to these customers could materially harm the business and results of operations.
• If any laboratory facilities become inoperable or inaccessible, or if additional laboratory space is not obtained, the company may be unable to perform tests or maintain desired turnaround times.
• Dependence on information technology systems; any material failure, delays, or cybersecurity breaches could materially harm the business.
• Any inability to obtain additional capital when needed and on acceptable terms may limit the ability to execute business plans, and liquidity needs could be materially affected by market fluctuations.
• If funds are raised by issuing equity securities, stockholders may experience substantial dilution.
• Impairment charges relating to goodwill and intangible assets could negatively affect financial performance (e.g., $120.2 million goodwill impairment in 2023).
• Ability to achieve or sustain profitability depends on successful collection of payment for tests, which may not be achieved.
• Failure to comply with government laws and regulations related to submission of claims for services could result in significant monetary damages, penalties, and exclusion from Medicare and Medicaid programs.
• Subject to governmental audits and investigations, such as the HRSA Audit and DOJ CIDs related to COVID-19 testing reimbursements, that could result in material refunds or settlements.
• Changes in federal laws, regulations, or enforcement policies with respect to marketing clinical laboratory tests, or violations of laws/regulations, could materially and adversely affect the business.
• Failure to comply with applicable federal, state, local, and foreign laboratory licensing requirements could lead to loss of ability to perform tests and material business disruptions.
• Broad legal requirements regarding information tested and analyzed; any failure to comply could result in significant penalties, reputational damage, and harm to the business.
• Product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their future commercial viability.
• Any product candidate developed will be subject to extensive regulation by the FDA and foreign authorities, with satisfaction of requirements being costly, time-consuming, uncertain, and subject to delays.
• Inability to obtain and maintain patent protection for any product candidate could allow competitors to develop and commercialize similar products.
• Reliance on trade secret protection, non-disclosure agreements, and invention assignment agreements may not be effective in protecting proprietary information.
• Litigation or other proceedings or third-party claims of intellectual property infringement or misappropriation could require significant time and money and prevent sales or development.
• May be subject to claims challenging the inventorship of patents and other intellectual property.
• Developments in patent law (e.g., Supreme Court decisions like Prometheus, Myriad, Alice) could have a negative impact on the business.
• Obtaining and maintaining patent protection depends on compliance with various procedures, and non-compliance could reduce or eliminate patent protection.
• Future issued patents covering product candidates could be found invalid or unenforceable if challenged.
• Patent terms may be inadequate to protect the competitive position of products and services for an adequate amount of time.
• Failure to obtain patent term extension and/or data exclusivity for product candidates may materially harm the business.
• Inability to enforce intellectual property rights outside the United States.
• Third parties may assert that employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
• An active, liquid trading market for common stock may not be sustained, making it difficult for stockholders to sell shares.
• The price of common stock may be volatile, and stockholders could lose all or part of their investment.
• Future issuances of common stock or rights to purchase common stock could result in additional dilution and cause the stock price to fall.
• No intention to pay dividends on common stock, so any returns will be limited to the value of common stock.
• Provisions in charter documents and Delaware law could discourage, delay, or prevent a change in control or management.
• Holders of common stock could be adversely affected if preferred stock is issued.
• Designation of the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain stockholder actions could limit stockholders' ability to obtain a judicial forum they consider favorable.
• Exposure to additional business, regulatory, political, operational, financial, and economic risks related to international operations, including the joint venture in China and U.S. economic/trade sanctions.
• Could face substantial liabilities that exceed resources for litigation relating to product or professional liability.
• Inflation has and may again materially and adversely affect the company by increasing costs.
• Inability to maintain effective internal control over financial reporting could lead to loss of confidence in financial information.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Investments in marketable securities are subject to certain risks which could affect overall financial condition.
• Maintaining cash deposits in excess of federally insured limits exposes the company to risks from adverse developments affecting financial institutions.
• Political uncertainty may have an adverse impact on operating performance and results of operations.
• U.S. federal government contracts are generally subject to terms more favorable to the customer.
• Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations.
• If hazardous materials used in operations cause contamination or injury, the company could be liable for resulting damages.
• If deemed an investment company under the Investment Company Act of 1940, applicable restrictions could make it impractical to continue business as currently conducted.
• Could be adversely affected by violations of the FCPA and other anti-bribery laws.
• Services present the potential for embezzlement, identity theft, or other similar illegal behavior by employees, consultants, or service providers.
• Could be adversely affected by alleged violations of the FTC Act or other truth-in-advertising and consumer protection laws.
• Even if IVD medical device products receive regulatory approval or certification, the company will continue to be subject to extensive regulatory oversight.
• Product candidates may cause undesirable side effects that could delay or prevent marketing approval, limit commercial profile, or result in significant negative consequences.
• If product candidates are approved, inability to develop sales, marketing, and distribution capabilities or enter into agreements with third parties could prevent successful commercialization.
• Reliance on third parties to conduct portions of clinical trials and non-clinical studies; non-performance could delay development programs.
• Reliance on third parties to supply and manufacture product candidates; failure to provide sufficient quantities, acceptable quality, or maintain regulatory compliance could stop or delay commercialization.

Future Outlook

The company expects research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other pre-clinical studies. It anticipates reduced revenues from a significant laboratory customer in 2026, particularly through the second quarter, as this customer begins performing certain tests internally. The company plans to offset this decline by developing existing customers and capturing new ones, and intends to improve profitability by optimizing margins and expanding into new markets, though these efforts are subject to risks and may not be successful. Cash provided by operations is expected to fluctuate, and the company may seek additional capital through various financing transactions, which could dilute existing stockholders.

Management Comments

• "We were pleased with the launch of our Ultra Rapid Whole Genome Sequencing service in 2025."
• "We believe our ability to continue to offer more genes and more ordering flexibility than our competitors could be a key contributor to the long-term growth of our business."
• "We believe this low internal cost is a key factor in our ability to grow our business and obtain margins on our sales that allow us to drive toward sustained profitability."
• "We expect to incur more operating expenses and use more cash in operating activities in the coming year as a result of our planned and ongoing clinical trials for FID-007 and FID-022, and as we continue to invest resources to grow our laboratory services business."
• "We intend to improve our profitability by improving margins and expanding in new markets for our tests, but these efforts are subject to risks... and may not be successful."

Industry Context

StockSavvy.ai notes that Fulgent Genetics operates in a highly competitive and rapidly evolving genetic testing and biopharmaceutical industry. The company's strategic acquisitions and R&D investments in nano-drug delivery and ADCs align with broader trends towards precision medicine and targeted cancer therapies. However, the industry faces increasing regulatory scrutiny, particularly regarding LDTs and AI use, and pricing pressures from government and private payors, which could impact profitability and market acceptance. The ongoing consolidation in the clinical diagnostic testing field also intensifies competition, requiring companies to continuously innovate and manage complex regulatory landscapes.

Comparison to Industry Standards

• The company's gross margin improvement from 38% to 41% in 2025 is a positive indicator, suggesting improved operational efficiency, but a direct comparison to industry averages or specific competitors like Quest Diagnostics or LabCorp would require external industry data not provided in the filing.
• The advancement of FID-007 into Phase 2 and FID-022 into Phase 1/1b clinical trials positions Fulgent Pharma in the competitive cancer therapeutics space, alongside major players like Bristol-Myers Squibb and academic institutions. Pre-clinical studies for FID-022 showed superior efficacy over irinotecan, and FID-007's PK profile was comparable to nab-paclitaxel, indicating competitive potential, but clinical trial results are still emerging.
• The company's reliance on Illumina as a sole supplier for NGS sequencers is a common industry challenge, shared by many genetic testing companies, highlighting a potential supply chain vulnerability.
• The CE certification under IVDR for its germline NGS system demonstrates compliance with stringent European regulatory standards, which is a competitive advantage for international market access, aligning with global benchmarks for diagnostic product quality and safety.

Corporate Governance

Legal Proceedings

• Subject to an ongoing Civil Investigative Demand (CID) issued by the U.S. Department of Justice (DOJ) under the False Claims Act, investigating allegations of medically unnecessary laboratory testing, improper billing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law.
• Subject to an ongoing audit inquiry from the U.S. Health Resources and Services Administration (HRSA) regarding reimbursement for COVID-19 tests furnished to patients believed to be uninsured (approximately $548.9 million recorded from HRSA in 2020-2022).
• Received a CID issued by the DOJ related to the HRSA Uninsured Program investigation.
• A qui tam complaint alleging false claims for reimbursement for COVID-19 tests was unsealed in February 2026 and subsequently dismissed without prejudice as to the relator and the U.S. government.
• Recorded an accrual of $14.5 million in connection with the settlement of a professional liability matter, with potential partial coverage from professional liability insurance.

Related Party Transactions

• Linda Dong, a member of the board of directors, is the Senior Executive Vice President of AHMC Healthcare Inc. The company performs genetic testing and other services for AHMC on an arms-length basis, recognizing insignificant revenue in 2025 and 2024, and $0.1 million in 2023.
• Prior to April 25, 2025, Ming Hsieh, the Chief Executive Officer and Chairperson of the board of directors, was on the board of directors and an approximately 20% owner of ANP Technologies, Inc. Ray Yin, President and Chief Scientific Officer of Fulgent Pharma, is the Founder, President, and Chief Technology Officer of ANP.
• The company incurred $0.6 million in expenses related to ANP licensing and development services in 2025 (prior to April 25, 2025), and $2.1 million in 2024, and $2.4 million in 2023.
• The company acquired 100% of the outstanding equity of ANP Technologies, Inc. in July 2025, which included the settlement of all outstanding liabilities and receivables between the entities.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances, volatility in stock price, and no anticipated dividends, with significant control exerted by principal stockholders and management.
• Employees benefit from a comprehensive compensation program, expansive benefit offerings, and ongoing professional development and mandatory training programs, with a focus on workplace safety.
• Customers are offered a broad and flexible test menu, affordable pricing, and a patient-centric telemedicine platform (Picture Genetics), but may experience impacts from reduced demand from large institutional customers and potential changes in regulatory oversight.
• Suppliers, particularly Illumina as the sole supplier for next-generation sequencers, represent a concentration risk for the company's laboratory operations.
• Creditors are impacted by the company's strong cash position, which reduces immediate reliance on external credit facilities, but also by the company's history of losses and ongoing legal/regulatory uncertainties.

Next Steps

• Complete the acquisition of Bako Diagnostics and StrataDx in the first half of 2026.
• Announce interim findings for FID-007 Phase 2 clinical trial in June 2026.
• Expect a full data readout for FID-007 Phase 2 clinical trial by the second half of 2027.
• Plan to investigate FID-007 in a Phase 3 registrational clinical trial in patients diagnosed with H&N squamous cell carcinoma, to initiate as early as the first half of 2027, assuming favorable Phase 2 results.
• Determine a maximum tolerated dose for FID-022 Phase 1/1b clinical trial within the next year.
• Continue to invest in research and development activities, particularly for FID-007 and FID-022 clinical trials.
• Focus on developing existing customers and capturing new customers to offset anticipated revenue decline from a large customer.
• Continue to monitor the therapeutic development reporting unit for impairment.
• Continue to monitor investments for changes in facts and circumstances that may indicate further impairments or observable price changes.
• Continue to comprehensively protect all personal information and comply with applicable privacy laws.
• Continue to evaluate the need to grow the size of the sales team and marketing resources.
• Expect cash receipt in 2026 for $106.1 million of ITCs carried back to 2021 and 2022 tax years.

Key Dates

Recommendation

The company shows promising growth in revenue and strategic expansion through acquisitions and therapeutic development. However, the significant increase in net loss, substantial cash burn from operations, and the anticipated decline in revenue from a major customer introduce considerable financial uncertainty. The ongoing legal and regulatory investigations also present unquantified risks. A 'Hold' recommendation is appropriate as investors should monitor the resolution of these financial and legal challenges and the progress of the therapeutic pipeline before making further investment decisions.

Keywords

Genetic Testing, Precision Medicine, Cancer Therapeutics, Nanoencapsulation, Diagnostic Services, Biopharma, Clinical Trials, SEC Filing, 10-K, Fulgent Pharma, FID-007, FID-022, ADC, Laboratory Services, Corporate Governance, Risk Management, Financial Performance, Healthcare Regulation, Intellectual Property, NASDAQ, Acquisitions, Investment Tax Credits